Aliso Viejo-based Focal Therapeutics Inc. raised about $3.8 million in venture capital, according to a Securities and Exchange Commission filing.
Focal makes a tissue-marking device called BioZorb to help surgeons, oncologists and other clinicians identify and delineate in three dimensions a surgical site for tissue removal.
The filing said 28 investors participated in the funding but didn’t disclose names or plans for use of the proceeds. It indicated Focal is seeking about $1.2 million in additional funding, for a total of $5 million in this round.
The company raised $3.5 million in Series C money in August 2014 from Okapi Venture Capital in Laguna Beach and Emergent Medical Partners in Portola Valley, according to CrunchBase.
—Vita Reed
